NSE · MEDIORG
Medicamen Organics Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹23 Cr with net profit ₹-4 Cr — a -17.7% net margin, versus 10.57% the period before.
Shareholding
As of 2026-09-30
- Promoter54.89%
- Public45.05%
- FII0.05%
445 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.68× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #1 of 51 by market cap · medians across 44 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,80,675 Cr | 83.22 | 9.81 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹52,297 Cr | 45.64 | 5.05 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹41,333 Cr | 32.73 | 8.51 | 25.99% | 20.31% |
| Rubicon Research Limited | ₹27,468 Cr | 95.31 | 19.38 | 22.94% | 15.47% |
| Shilpa Medicare Ltd. | ₹18,431 Cr | 64.81 | 6.68 | 12.05% | 18.05% |
| Caplin Point Laboratories Ltd. | ₹18,110 Cr | 27.22 | 5.37 | 17.88% | 29.09% |
| Eris Lifesciences Limited | ₹17,122 Cr | 22.87 | 4.12 | 17.07% | 21.36% |
| Marksans Pharma Limited | ₹13,764 Cr | 24.59 | 4.13 | 16.8% | 16.51% |
| Bliss GVS Pharma Ltd. | ₹6,535 Cr | 40.17 | 4.97 | 12.49% | 15.01% |
| Senores Pharmaceuticals Limited | ₹5,347 Cr | 40.06 | 5.32 | 13.31% | 18.57% |
| Medicamen Organics Ltd.(this company) | — | 6.27 | 1.09 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashMedicamen Organics Ltd., operating in the Pharmaceuticals sector, has a market capitalization of Rs 119 Cr. The company's revenue growth was 51.11%. The book value per share is Rs 23.68.
Positives
- +Revenue grew by 51.11%.
- +Net profit increased from Rs 0.2981 Cr in Mar 2021 to Rs 4.0471 Cr in Mar 2025.
- +The company's Return on Capital Employed (ROCE) is 14.04%.
- +The debt-to-equity ratio is 0.55, indicating a manageable debt level.
- +Promoter holding of 54.8924% as of June 30, 2026, is above 50%.
Negatives
- −The EPS is negative at - Rs 2.5.
- −The company is currently under LT-ASM (Additional Surveillance Measure) Stage 1.
- −No quarterly results have been disclosed in the provided data.
- −Promoter holding decreased from 61.268% in January 2026 to 54.8924% in June 2026.
- −The 'about' field for the business activities is null.
Financial Performance
The company's revenue increased from Rs 25.0596 Cr in Mar 2021 to Rs 38.2827 Cr in Mar 2025. Net profit also showed an upward trend, rising from Rs 0.2981 Cr in Mar 2021 to Rs 4.0471 Cr in Mar 2025. Earnings per share (EPS) grew from Rs 0.5 in Mar 2021 to Rs 3.66 in Mar 2025.
Profitability & Returns
Medicamen Organics Ltd. reported a Return on Capital Employed (ROCE) of 14.04%. The Earnings Per Share (EPS) for the most recent period was - Rs 2.5.
Balance Sheet
The company maintains a debt-to-equity ratio of 0.55. The book value per share is Rs 23.68.
Ownership & Pledges
Promoter holding stands at 54.8924% as of June 30, 2026. There are no promoter shares pledged.
Regulatory & Surveillance
Medicamen Organics Ltd. is currently under LT-ASM (Additional Surveillance Measure) Stage 1.
Data as of — price: 2026-11-07 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.